Freeline Therapeutics is a biotechnology company focused on developing liver directed gene therapies for a range of diseases.
Freeline Therapeutics has raised €178M across 2 funding rounds from 4 investors, most recently a Series C round in Jul 2020. Based in Stevenage, UK; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2020-07-05 | Series C | €71M | Eventide Asset Management,Novo Holdings,Wellington Management | View deal → |
| 2020-07-05 | Series C | €107M | Eventide Asset Management,Novo Holdings,Syncona Partners LLP,Wellington Management | View deal → |
